# KLOW Peptide — Four-Node Research Blend: KPV, GHK-Cu, BPC-157 and TB-500 > KLOW peptide is a four-component research blend. Component-level findings from peer-reviewed studies. No controlled blend trial exists. A literature digest. Component findings summarized from the peer-reviewed record. No controlled blend trial exists. One honest gap drawn into the schematic. ## In plain English KLOW peptide is not a single molecule. It is a research blend of four separate peptides — KPV, GHK-Cu, BPC-157 and TB-500 — co-dissolved in one vial. Each of the four has its own published research record. None of the four is FDA-approved for human use. And the four-peptide blend itself has never been tested in any controlled study. That last point matters: any claim that the combination does more than each peptide alone is an extrapolation, not a finding. The research community uses the blend for recovery and repair contexts — mainly connective tissue, inflammation and wound healing. The component studies support this direction. TB-500 (or rather the related full-length protein thymosin beta-4) accelerated wound closure by 42% at four days in a rat model [1]. BPC-157 accelerated tendon repair in rats across biomechanical and functional measures [2]. KPV suppressed inflammatory signaling in gut epithelial cells [3]. GHK-Cu drove matrix synthesis and gene-expression shifts in fibroblasts [4]. What people report from the blend — and what to watch for — is on [the effects page](/effects). ## What is KLOW peptide KLOW peptide is a co-formulated research blend of four chemically distinct peptides. The most common research-vial composition is 80 mg total: GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, KPV 10 mg. GHK-Cu (glycyl-histidyl-lysine copper complex, CAS 89030-95-5, MW 402.92 Da) is the mass-dominant component at roughly 62.5% of the total. It is a copper-chelated tripeptide (that is, three amino acids bound 1:1 to a copper ion) studied for collagen synthesis, extracellular-matrix remodeling and broad transcriptomic effects in skin fibroblasts. KPV (lysine-proline-valine, CAS 67727-97-3, MW 342.44 Da) is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (the last three amino acids of a 13-residue hormone). It is the anti-inflammatory arm: a substrate of the PepT1 (SLC15A1) transporter (Km ~160 microM) that carries it into inflamed gut and immune cells, where it inhibits NF-kappaB nuclear import and reduces inflammatory cytokine output [3]. BPC-157 (body protection compound 157, CAS 137525-51-0, MW 1419.53 Da) is a synthetic 15-amino-acid peptide derived from a gastric-juice protein. It activates the VEGFR2/PI3K/Akt/eNOS angiogenesis pathway (VEGFR2 is the receptor that initiates new blood-vessel growth) and upregulates the growth-hormone receptor in tendon fibroblasts [2]. TB-500 (Ac-LKKTET-Q, MW 889.02 Da) is an N-acetylated seven-amino-acid fragment of the native 43-residue protein thymosin beta-4. It carries the actin-binding motif of the parent protein. Most foundational efficacy data — including the wound re-epithelialization findings — are for full-length thymosin beta-4, not the short fragment. The distinction matters and is detailed in the [blend components](/blend-components) page. ## KLOW blend The KLOW peptide blend is a co-formulation, not a chemical complex. The four peptides remain separate molecules in solution; they do not fuse into a single new compound. The combination rationale is mechanistic: KPV addresses cytokine signaling, GHK-Cu addresses matrix synthesis and copper supply, BPC-157 addresses the angiogenic axis (new blood-vessel formation), and TB-500 / thymosin beta-4 addresses cell migration and re-epithelialization (the closure of the outer tissue layer over a wound). The four arms are theoretically complementary steps in a tissue-repair cascade. One inherent limitation: the four peptides have markedly different clearance rates. The tripeptides KPV and GHK-Cu clear far faster than BPC-157; and the short TB-500 fragment behaves differently from full-length thymosin beta-4. A single co-formulated dose cannot hold all four at matched exposures — a pharmacokinetic mismatch built into the vial. ## KLOW peptide benefits Component-attributed findings from the single-compound literature. The blend itself has no controlled study. **TB-500 arm (thymosin beta-4):** In a rat full-thickness wound model, topical or IP thymosin beta-4 increased re-epithelialization (regrowth of surface tissue) by 42% at four days and up to 61% at seven days versus saline, with increased wound contraction (greater than or equal to 11% by day 7) and raised collagen deposition and angiogenesis. As little as 10 pg stimulated keratinocyte migration two- to three-fold [1]. A separate rodent study documented concurrent angiogenesis, wound healing and hair-follicle effects [12]. **BPC-157 arm:** Fully transected rat Achilles tendons healed better on biomechanical, functional, microscopic and macroscopic measures with IP BPC-157 (10 microg, 10 ng or 10 pg/rat/day) versus untreated controls; in vitro tendocyte outgrowth was also stimulated [2]. A 2026 review covering BPC-157 for musculoskeletal conditions confirms favorable tissue-repair outcomes in animal models, while noting human safety data remain scarce [7]. **GHK-Cu arm:** Topical GHK-Cu increased collagen production in 70% of treated women vs 50% for vitamin C and 40% for retinoic acid. Plasma GHK naturally declines from ~200 ng/mL at age 20 to ~80 ng/mL by age 60. In vitro, nanomolar GHK-Cu stimulates procollagen-I, procollagen-IV, dermatan sulfate, chondroitin sulfate and the proteoglycan decorin [4]. **KPV arm:** Nanomolar KPV reduced NF-kappaB and MAPK activation and pro-inflammatory cytokine secretion in human intestinal epithelial cells and T cells in culture; oral KPV reduced the severity of two chemically induced colitis models in mice [3]. See [KLOW effects](/effects) for what researchers in the community report, clearly labeled as anecdotal. ## KLOW vs glow GLOW and KLOW are distinct blends. GLOW does not contain KPV. KLOW adds KPV as its anti-inflammatory fourth arm — the PepT1-mediated NF-kappaB suppressor [3]. The two blends share the GHK-Cu, BPC-157 and TB-500 components but differ in the fourth position and in total composition. Neither blend has been tested as a combination in any controlled study. WOLVERINE is a separate blend again and is outside the scope of this site. ## KLOW peptide blend The KLOW peptide blend is not a weight-loss or metabolic compound. None of its four components is a GLP-1 receptor agonist (the receptor class behind incretin-based drugs) or an established metabolic or appetite-regulating agent. The blend's research context is tissue repair and inflammation, not weight management. Any vendor framing KLOW as a weight-loss agent is unsupported by the component literature. --- A blueprint of the component literature — four peptides drawn against their own studies, the untested blend left as the one honest empty node.